ESH CLL 2022 | Treatment approaches to CLL with high-risk molecular features
In this video, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses treatment approaches to chronic lymphocytic leukemia (CLL) with high-risk molecular features. Dr Kater first highlights the ongoing debate regarding the use of chemotherapy versus chemotherapy-free regimens in CLL, with focus on immunoglobulin heavy chain gene (IgHV)-mutated and unmutated patients. Dr Kater explains that in many cases, if there is no clear overall survival benefit, chemotherapy-based regimens are still offered to patients. To conclude, Dr Kater emphasizes the importance of physicians and patients working together when making decisions on treatment, and briefly talks on the treatment of NOTCH1-mutated CLL patients with antibodies. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Research funding Abbvie, Gennetech, Janssen, AZ, BMS
